Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_assertion type Assertion NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_head.
- NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_assertion description "[Our results suggest that patients with HER2(+) breast cancer may benefit from anti-TBK1/IKK? plus anti-HER2 combination therapies and establish conditions that can be used to screen for additional TIC-specific inhibitors of HER2(+) breast cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_provenance.
- NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_assertion evidence source_evidence_literature NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_provenance.
- NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_assertion SIO_000772 24487029 NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_provenance.
- NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_assertion wasDerivedFrom befree-2016 NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_provenance.
- NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_assertion wasGeneratedBy ECO_0000203 NP1151174.RAKN7F5ETcQUGhHELuW1xIU8_gZK5TvI58Cmou9j8ouWY130_provenance.